research The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta‐Analysis Study
Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
Search
for
Sort by
Research
510-540 / 1000+ results
research Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn’s disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient
Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
research Loss of TET2 Tips the Scales Toward Tumorigenesis
Loss of TET2 increases the risk of skin and oral cancer.
research Baricitinib in pediatric chronic immune thrombocytopenia and associated autoimmune conditions: a case report
Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
research Role of sgk1 in cancer: a bibliometric analysis from 2013 to 2023—review article
SGK1 is important in cancer growth and treatment resistance, and targeting it could improve therapies.
research New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics
New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
research Dihydrotestosterone induces p27 degradation via direct binding with SKP2 in ovarian and breast cancer
Dihydrotestosterone causes p27 protein breakdown in ovarian and breast cancer cells by binding with SKP2.
research Identification of novel hair‐growth inducers by means of connectivity mapping
Fluphenazine and iloprost can induce hair growth.
research Upadacitinib in dermatologic therapy: Emerging evidence and expanding indications
Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.
research Upadacitinib: A New Weapon for the Treatment of Twenty-Nail Dystrophy
Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research Induction of ornithine decarboxylase in specific subpopulations of murine epidermal cells following multiple exposures to 12-O-tetradecanoylphorbol-13-acetate, mezerein and ethyl phenylpropriolate
TPA strongly increases ODC activity in certain skin cells, potentially aiding tumor growth.
research Efficacy of Ritlecitinib in Patients with Alopecia Areata by Extent of Hair Loss: Results from the Phase 2b/3 and Phase 3 ALLEGRO Clinical Trials
Ritlecitinib effectively promotes hair regrowth in severe and very severe alopecia areata.
research Cemiplimab-Induced Alopecia Areata
A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.
research 5-Bromo-2′-deoxyuridine induced effluvium via p53-mediated CD326-positive keratinocyte apoptosis in C57BL/6 mice
A chemical called 5-Bromo-2′-deoxyuridine caused rapid hair loss in mice by killing certain skin cells through a specific cell death pathway.
research Data from Spontaneous Squamous Cell Carcinoma Induced by the Somatic Inactivation of Retinoblastoma and Trp53 Tumor Suppressors
Loss of the p53 gene alone causes tumors, and losing both p53 and Rb genes speeds up aggressive skin cancer.
research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
research Successful treatment of epidermal growth factor receptor inhibitor–induced alopecia with doxycycline
Doxycycline can effectively treat hair loss caused by EGFR inhibitors.
research The manipulation of the cedrol metabolism pathway by baricitinib and its immune interaction mechanism against chemotherapy-induced alopecia
research Reply to: The ends of a conundrum?
K10 may not prevent tumors as previously thought and might increase benign tumor risk.
research Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
research Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with AIRE gene mutation (autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy, APECED syndrome) treated with ruxolitinib
Ruxolitinib helped a patient with alopecia areata regrow hair.
research Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor
ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.
research The Dark Side of Gefitinib: Reflectance Confocal Microscopy Applied to Hair Hyperpigmentation
Gefitinib can cause hair and eyebrow darkening.
research Upregulation of genes orchestrating keratinocyte differentiation, including the novel marker gene ID2, by contact sensitizers in human bulge‐derived keratinocytes
The ID2 gene can help distinguish between sensitizers and irritants in skin cells.
research Cytotoxicity of bendamustine, alone and in combination with novel agents, toward adult T-cell leukemia cells
Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.
research 1272 p21Waf1/Cip1 is differentially expressed in epidermal versus follicular melanocytes and melanoma cells and is phenotypically regulated by UVB-mediated apoptosis
The protein p21 is more abundant in normal skin cells than in melanoma cells and may help protect against melanoma, with UVB light affecting its levels.
research Deregulated expression of E2F1 induces hyperplasia and cooperates with ras in skin tumor development
Overexpression of E2F1 can lead to skin tumors and disrupt hair growth.
research Immune checkpoint inhibitor‐related alopecia: Insight into the pathophysiology utilizing non‐invasive diagnostic techniques
Immune checkpoint inhibitors used in cancer therapy can cause hair loss, and understanding this can help manage the side effect.
research NEW NON SYNTHETIC MOLECULES ARE ABLE TO INHIBIT APOPTOSIS IN DERMAL PAPILLAR CELLS OF HAIR BULB
New molecules can prevent cell death in hair follicles.